Faron mave

  https://www.jnj.com/innovation/the-future-of-immunology   "Protecting from invaders and surveilling for other threats is a big job—and it’s what your immune system , your body’s very own built-in defense mechanism , does every day. When you catch a cold or other viral infection, for instance, your immune system mounts a response that mobilizes killer T cells and triggers the release of antibodies , which identify the virus as harmful and destroy it . Mission accomplished. Your immune system then quiets back down and you feel better. If you have an autoimmune condition, however, that’s not what happens. Instead, your immune system mistakenly treats your body’s normal tissue as an invader and attacks it, which causes chronic inflammation. Research published in The Lancet in 2023 suggests one in 10 people around the world live with an autoimmune disease, an umbrella term that pertains to over 100 conditions The most common antibody is immunoglobulin G (IgG) and the...

Updated full data from Faron's Phase 1/2 BEXMAB study   Deep and durable responses in HR-MDS with favorable safety profile   https://mfn.se/a/faron-pharmaceuticals/faron-presents-updated-bexmab-data-at-ash-2025-deep-and-durable-responses-in-hr-mds-with-favorable-safety-profile    Significant efficacy observed in TP53-mutated patients with a 70% complete remission rate in the frontline HR MDS Key highlights: Median overall survival (mOS) with bexmarilimab and azacitidine in relapsed/refractory (r/r) HR-MDS patients reached 14.5 months (increased from 13.4 months observed earlier), a significant improvement in a population with historically poor survival of only 5-6 months In treatment-naïve patients with HR-MDS and TP53 mutation, the combination achieved a remarkable 70% complete remission (CR) rate Deep responses allowed 50% of treatment-naïve TP53-mutated patients and 21% of r/r TP53-mutated patients to proceed to stem cell transplant (SCT) For the first ...

  https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1190379/full   Deep Shah,  Brian Soper,  Lindsay Shopland Front. Immunol. , 25 May 2023  Sec. Cancer Immunity and Immunotherapy  Cancer is the leading cause of death worldwide. Cancer immunotherapy involves reinvigorating the patient’s own immune system to fight against cancer. While novel approaches like Chimeric Antigen Receptor (CAR) T cells, bispecific T cell engagers, and immune checkpoint inhibitors have shown promising efficacy, Cytokine Release Syndrome (CRS) is a serious adverse effect and remains a major concern. CRS is a phenomenon of immune hyperactivation that results in excessive cytokine secretion, and if left unchecked, it may lead to multi-organ failure and death.   https://www.researchgate.net/figure/Components-of-the-immune-system-The-immune-system-is-divided-into-innate-and-adaptive_fig1_351122708       (humoral: in liquid) ...

Stakeholders in drug development  https://mxschons.com/2023/stakeholders-in-drug-development-drug-development-101-series/      Sponsors such as pharmaceutical companies that oversee the process and assume responsibility for bringing a drug to market; Vendors   provide specialised services in areas like clinical trials and manufacturing and study sites who run trials and recruit participants ; > To put phase III into execution needs heavier investments and big pharmas are needed to invest on it for licenses or product. They are not necessarily specialized on routines, but hire vendors. https://www.stellarmr.com/report/Clinical-Trials-Market/802   (First referred on 9.12.2024 and 8.11.2024) "The increasing need for coordination and collaboration in research is the key factor that would contribute to the growth of the Clinical Trials Market during the forecast period. The pandemic highlighted the need for quick mobilization and integration of di...

"A SWOT analysis is a strategic planning tool used to identify the Strengths, Weaknesses, Opportunities, and Threats of a project, business, or personal goal   " https://www.ibisworld.com/blog/how-to-do-a-swot-analysis/1/1127/       How do partners, competitors or possible buyers evaluate Faron? WE can evaluate them... Threats are the strongest driving forces in their minds.  Toolkit: https://phw.nhs.wales/services-and-teams/improvement-cymru/improvement-cymru-academy1/resource-library/academy-toolkit-guides/swot-analysis-toolkit/   As a driving force 1 are strengths of Faron  As a driving force 2 are the threats of Big Pharma itself... Let us make an example, of current interest - AZA:  https://mdspatientsupport.org.uk/what-is-mds/azacitidine-vidaza/   "Hypomethylating agents are less intensive than other types of chemotherapy.  The aim of hypomethylating agents is to slow the progression of the disease while at the same tim...

The development is ongoing strongly and the signs are good.  https://meetings-api.hematology.org/api/abstract/vmpreview/296056    Publication Number: 236   Efficacy, molecular and translational analysis of TP53-mutated HR-MDS with bexmarilimab and azacitidine: Updated results from the bexmab Phase 1/2 study  "Bexmarilimab enhances macrophage antigen presentation and T cell activation. Thus, bexmarilimab may favourably alter the dysregulated BM immune microenvironment in mTP53 MDS. Simultaneously, bexmarilimab can increase the efficacy of cytotoxic agents, such as HMAs, by targeting Clever-1 on malignant blasts and altering energy production of the malignant cells."  Authors: Amer Zeidan (1), Anthony Stein (2), Johanna Rimpiläinen (3), Marja Pyörälä (4), Timo Siitonen (5), Brian Ball (2), Mikko Myllymäki (6), Joshua Zeidner (7), Dr. Emma Searle (8), Ruth Witherall (9), Petri Bono (10), Aneel Nimba (10), Joab Williamson (10), Sofia Aakko (10), Maija...

In the big picture Bexmarilimab is a novel treatment activating the body  to protect itself via   immunotherapy . Fatal diseases force to act at most effective ways, but there is a danger that the body itself may be hurt. Finally it is the  question of balance - a fine adjustment. "In combination with standard-of-care, and in both solid tumors and hematologic malignancies, bexmarilimab may improve the efficacy of current cancer treatments and bring the promise of immunotherapy to a broader population." The clinical tests have been initiated  on hematologic malignancies  because of simplier test protocols by blood samples. Chart sample and technical analysis https://www.marketscreener.com/quote/stock/FARON-PHARMACEUTICALS-OY-24949011/graphics/   An interval of one week; typical start-up company behaviour